2012 Agenda
Pharmaceutical Strategic Alliances:
Building Sustainable Value Through New Relationships
As it searches for innovation to fuel sustainable growth, biopharma is dramatically reinventing its relationships across the board. Once entirely confident of its own strengths, the industry is displaying a new sensitivity to creative collaboration. Adaptive business models are selectively emerging. As parts of the heavily interdependent life sciences ecosystem undergo multi-year transformations, Big Pharma is acknowledging its responsibilities in propping up valuable, but capital-starved sources of long-term innovation. Getting closer to the patient is vital to the process. The result is novel cooperation among traditionally wary constituents: pharma, biotech, payers, providers and patients.
But can these arrangements, which aim to provide all parties with rewards and mitigate risk at various steps of the process deliver on value in a resource-constrained world? As pharma reaches further into emerging geographies, how does it balance growth in new markets with still-lucrative but shrinking opportunities at home? At this year's Pharmaceutical Strategic Alliances meeting we'll explore how companies can best use non-traditional partners to transform weak pipelines, jumpstart flagging revenues, and prove relevancy of their products to payers and health care providers.
Traditional alliances still have their place, though they represent a much smaller part of the strategic spectrum. Large drug companies are as apt to build relationships with venture capital partners, payers, data providers, academic centers, governments, and each other. These new relationships will generate ideas about industry's best paths forward – and create new pressures to find common ground with unfamiliar partners.
Monday, September 17, 2012
|
| 1:30-2:00pm |
Registration and Pre-Conference Workshops
|
| 2:00-3:30pm |
Workshop -- KHIDI |
| 3:30-3:45pm |
Break
|
| 3:45-5:00pm |
Workshop -- HillCo |
|
5:00-6:30pm
|
Welcome Reception and Registration
*Please join us for a drink and some hors d'oeuvres after these workshops.
|
Tuesday, September 18, 2012
|
|
7:45-8:30am
|
Registration & Continental Breakfast
|
|
8:30-8:45am
|
Welcome and Opening Remarks
|
|
8:45-9:30am
KEYNOTE
|
Fireside Chat
Chris Morrison (moderator)
Elsevier Business Intelligence
|
|
9:30-10:00am
|
Implementing Key Components for New R&D Models
|
|
10:00-11:00am
|
Keying on the Provider System to Establish Drug/Dx Value
Matt Zubiller
VP, Decision Management
McKesson Health Solutions
Robert Epstein, MD
President, United Biosource Corp.
Chief Clinical Research and Development Officer
Medco
Michael Nohaile
Global Head of Molecular Diagnostics
Novartis
Eric Schadt, PhD
Director, Institute for Genomics and Multiscale Biology
Mt. Sinai School of Medicine
|
|
11:00-11:30am
|
Networking Break
|
|
11:30-12:30pm
|
Tapping Into Reverse Innovation
Salomon Azoulay, MD
SVP, Medical & Development, Emerging Markets
Pfizer
|
|
12:30pm-2:00pm
|
LUNCH
|
|
2:00-2:45pm
|
Improving your Development Strategy
David-Alexandre Gros
Chief Strategy Officer
Sanofi
Bahija Jallal, PhD
EVP, Research & Development
MedImmune
|
|
2:45-3:45pm
|
Pharma Takes Notice Of Neglected Diseases
|
|
3:45-4:15pm
|
Networking Break
|
|
4:15-5:15pm
|
Oncology CEO Roundtable
Anthony Coles, MD
CEO
Onyx Pharmaceuticals
|
|
6:00-8:00pm
|
Cocktail Reception
|
Wednesday, September 19, 2012
|
|
7:45-8:25am
|
Registration & Continental Breakfast
|
|
8:25am
|
Welcome and Recap
Chris Morrison
Elsevier Business Intelligence
|
|
8:30-9:15am
|
Dealmaking Trends: Current Data and Strategies
Chris Morrison
Elsevier Business Intelligence
|
|
9:15-10:15am
|
Building Biotech Value: New Models for Modern Times
Kevin Starr
Partner
Third Rock Ventures
Kurt Graves
Executive Chairman
Intarcia
Warren Huff
CEO
Reata
Steve Tregay
CEO
FORMA
|
|
10:15-10:45am
|
Networking Break and Check-Out
|
|
10:45-12:00pm
|
Business Development: Do More with Less
Shaun Grady
VP, Strategic Partnering and Business Development
AstraZeneca
Roger J. Pomerantz, MD, FACP
World Wide Head of Licensing and Acquisitions and SVP
Merck
Nigel Sheail
Head of Global Business Development & Licensing
Bayer AG
|
|
12:00-1:00pm
|
Maximizing Value in a New Commercial Landscape
Adam Schechter
President, Global Human Health
Merck & Co.
Kevin Buchi
VP, Global Brands
Teva Pharmaceuticals
|
|
1:00pm
|
Box Lunch
Conference Concludes
|